Total Payments
$233,725
2024 Payments
$141,042
Companies
11
Transactions
57
Medicare Patients
14,776
Medicare Billing
$11.9M
Payment Breakdown by Category
Research$225,809 (96.6%)
Other$5,525 (2.4%)
Consulting$1,625 (0.7%)
Food & Beverage$726.67 (0.3%)
Gifts$38.80 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $225,809 | 23 | 96.6% |
| Current or prospective ownership or investment interest | $5,525 | 7 | 2.4% |
| Consulting Fee | $1,625 | 1 | 0.7% |
| Food and Beverage | $726.67 | 24 | 0.3% |
| Gift | $38.80 | 2 | 0.0% |
Payments by Type
Research
$225,809
15 transactions
General
$7,916
34 transactions
Ownership
$0
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EyePoint Pharmaceuticals US, Inc. | $140,932 | 1 | $0 (2024) |
| Hexal AG | $84,877 | 14 | $0 (2023) |
| US Retina LLC | $5,525 | 15 | $0 (2024) |
| Carl Zeiss Meditec, Inc. | $1,762 | 2 | $0 (2020) |
| Genentech USA, Inc. | $229.39 | 5 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $161.71 | 7 | $0 (2024) |
| Allergan, Inc. | $79.16 | 5 | $0 (2021) |
| Bausch & Lomb Americas Inc. | $52.47 | 3 | $0 (2024) |
| Carl Zeiss Meditec AG | $38.80 | 2 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $34.90 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $141,042 | 6 | EyePoint Pharmaceuticals US, Inc. ($140,932) |
| 2023 | $20,491 | 10 | Hexal AG ($20,366) |
| 2022 | $67,006 | 15 | Hexal AG ($64,511) |
| 2021 | $1,246 | 6 | US Retina LLC ($1,203) |
| 2020 | $2,399 | 6 | Carl Zeiss Meditec, Inc. ($1,625) |
| 2019 | $1,032 | 7 | US Retina LLC ($947.50) |
| 2018 | $354.79 | 4 | US Retina LLC ($323.00) |
| 2017 | $153.53 | 3 | Carl Zeiss Meditec, Inc. ($137.19) |
All Payment Transactions
57 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/01/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $28.97 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/24/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $24.77 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/09/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $36.50 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/09/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: Ophthalmology | ||||||
| 02/14/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | — | Cash or cash equivalent | $140,932.39 | Research |
| Study: A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME) • Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 2024 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 12/11/2023 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $17.01 | General |
| Category: Ophthalmology | ||||||
| 10/26/2023 | Hexal AG | — | — | Cash or cash equivalent | $11,245.98 | Research |
| Study: CSOK583A12301 | ||||||
| 10/26/2023 | Hexal AG | — | — | Cash or cash equivalent | $364.50 | Research |
| Study: CSOK583A12301 | ||||||
| 10/17/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $36.09 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/10/2023 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $16.12 | General |
| Category: Ophthalmology | ||||||
| 06/13/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/11/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $31.85 | General |
| Category: Ophthalmology | ||||||
| 03/09/2023 | Hexal AG | — | — | Cash or cash equivalent | $1,088.69 | Research |
| Study: CSOK583A12301 | ||||||
| 01/19/2023 | Hexal AG | — | — | Cash or cash equivalent | $7,666.79 | Research |
| Study: CSOK583A12301 | ||||||
| 2023 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 12/15/2022 | Hexal AG | — | — | Cash or cash equivalent | $8,388.51 | Research |
| Study: CSOK583A12301 | ||||||
| 10/27/2022 | Hexal AG | — | — | Cash or cash equivalent | $194.40 | Research |
| Study: CSOK583A12301 | ||||||
| 09/22/2022 | Hexal AG | — | — | Cash or cash equivalent | $10,795.46 | Research |
| Study: CSOK583A12301 | ||||||
| 09/20/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/16/2022 | Hexal AG | — | — | Cash or cash equivalent | $14,284.99 | Research |
| Study: CSOK583A12301 | ||||||
| 04/27/2022 | Hexal AG | — | — | Cash or cash equivalent | $194.40 | Research |
| Study: CSOK583A12301 | ||||||
| 04/13/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $2,025.75 | General |
| 04/12/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $304.00 | General |
| 04/12/2022 | Genentech USA, Inc. | SUSVIMO (Drug), VABYSMO | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: Immunology and Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME) | EyePoint Pharmaceuticals US, Inc. | $140,932 | 1 |
| CSOK583A12301 | Hexal AG | $84,877 | 14 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 3,393 | 63,378 | $6.6M | $3.3M |
| 2022 | 17 | 3,470 | 13,219 | $6.2M | $2.9M |
| 2021 | 15 | 3,813 | 12,012 | $6.4M | $3.1M |
| 2020 | 17 | 4,100 | 11,762 | $5.6M | $2.6M |
Total Patients
14,776
Total Services
100,371
Medicare Billing
$11.9M
Procedure Codes
68
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 190 | 53,101 | $2.2M | $1.5M | 68.5% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 221 | 1,666 | $2.1M | $1.2M | 55.3% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 1,022 | 2,675 | $535,000 | $246,647 | 46.1% |
| 67028 | Injection of drug into eye | Office | 2023 | 316 | 1,986 | $996,500 | $176,852 | 17.7% |
| 92134 | Imaging of retina | Office | 2023 | 1,011 | 2,698 | $377,720 | $82,025 | 21.7% |
| J3490 | Unclassified drugs | Office | 2023 | 19 | 33 | $99,000 | $56,591 | 57.2% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 12 | 240 | $48,000 | $28,887 | 60.2% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 204 | 204 | $51,000 | $22,262 | 43.7% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 16 | 16 | $40,000 | $14,678 | 36.7% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 127 | 132 | $26,400 | $14,607 | 55.3% |
| 67210 | Destruction of growth of retina using a laser | Office | 2023 | 16 | 21 | $31,500 | $8,625 | 27.4% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 11 | 12 | $30,000 | $8,529 | 28.4% |
| 92250 | Photography of the retina | Office | 2023 | 147 | 166 | $33,200 | $4,648 | 14.0% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 14 | 69 | $10,350 | $3,895 | 37.6% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 12 | 12 | $19,800 | $2,392 | 12.1% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 14 | 29 | $8,700 | $1,111 | 12.8% |
| 92020 | Exam of the internal drainage system of eye | Office | 2023 | 12 | 18 | $756.00 | $385.31 | 51.0% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 18 | 18 | $1,350 | $361.84 | 26.8% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 11 | 282 | $4,230 | $240.34 | 5.7% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 254 | 3,025 | $3.8M | $2.2M | 56.9% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 1,063 | 2,748 | $549,600 | $259,164 | 47.2% |
| 67028 | Injection of drug into eye | Office | 2022 | 309 | 1,903 | $955,000 | $171,845 | 18.0% |
| 92134 | Imaging of retina | Office | 2022 | 953 | 2,627 | $367,780 | $82,380 | 22.4% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 15 | 1,740 | $72,506 | $51,924 | 71.6% |
| J3590 | Unclassified biologics | Office | 2022 | 15 | 23 | $57,500 | $40,675 | 70.7% |
About Dr. Robert Parnes, MD
Dr. Robert Parnes, MD is a Ophthalmology healthcare provider based in Hagerstown, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407824360.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Parnes, MD has received a total of $233,725 in payments from pharmaceutical and medical device companies, with $141,042 received in 2024. These payments were reported across 57 transactions from 11 companies. The most common payment nature is "" ($225,809).
As a Medicare-enrolled provider, Parnes has provided services to 14,776 Medicare beneficiaries, totaling 100,371 services with total Medicare billing of $11.9M. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist, Surgery
- Location Hagerstown, MD
- Active Since 03/08/2006
- Last Updated 02/20/2023
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1407824360
Products in Payments
- EYP-1901 (Drug) $140,932
- VABYSMO (Drug) $150.00
- CIRRUS HD-OCT (Device) $137.19
- EYLEA HD (Biological) $101.56
- OZURDEX (Drug) $79.16
- XIPERE (Drug) $52.47
- Vabysmo (Drug) $48.32
- EYLEA (Biological) $43.81
- None Specified (Medical Supply) $38.80
- Syfovre (Drug) $31.85
- EYLEA AFLIBERCEPT INJECTION (Biological) $16.34
- SUSVIMO (Drug) $15.55
- Lucentis (Biological) $15.52
- BEOVU (Drug) $13.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Hagerstown
David Warrow, M.d, M.D
Ophthalmology — Payments: $79,434
Ophthalmology $79,434
Dr. Augustus Stern, M.d, M.D
Ophthalmology — Payments: $7,520
Ophthalmology $7,520
Kinga Huzella, M.d, M.D
Ophthalmology — Payments: $5,779
Ophthalmology $5,779
Dr. Adam Wenick, Md, Phd, MD, PHD
Ophthalmology — Payments: $5,101
Ophthalmology $5,101
Dr. John Wroblewski, Md, MD
Ophthalmology — Payments: $3,433
Ophthalmology $3,433
Mr. Erwin Puente, Md, MD
Ophthalmology — Payments: $2,704
Ophthalmology $2,704